Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis - Wikidata - wikimedia - TriplyDB

Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis

Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis

http://www.wikidata.org/entity/Q37085672

about

Molecular Imaging of Angiogenesis and Vascular Remodeling in Cardiovascular Pathology Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery Imaging and nanomedicine in inflammatory atherosclerosis Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents Prevention of Oxidized Low Density Lipoprotein-Induced Endothelial Cell Injury by DA-PLGA-PEG-cRGD Nanoparticles Combined with Ultrasound.Recent Advances in (19)Fluorine Magnetic Resonance Imaging with Perfluorocarbon Emulsions.Assessing the barriers to image-guided drug delivery.Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance.Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent.Imaging atherosclerosis and vulnerable plaque.Phase-shift, stimuli-responsive perfluorocarbon nanodroplets for drug delivery to cancer.A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke Perspectives and opportunities for nanomedicine in the management of atherosclerosis.Ultrasound-mediated tumor imaging and nanotherapy using drug loaded, block copolymer stabilized perfluorocarbon nanoemulsions Rationale for a nanomedicine approach to thrombolytic therapy.Multifunctional agents for concurrent imaging and therapy in cardiovascular disease Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases.Plasmonic nanobubbles as tunable cellular probes for cancer theranostics Nanomedicine strategies for molecular targets with MRI and optical imaging.Open access integrated therapeutic and diagnostic platforms for personalized cardiovascular medicine Conquering the dark side: colloidal iron oxide nanoparticles.Challenges associated with Penetration of Nanoparticles across Cell and Tissue Barriers: A Review of Current Status and Future Prospects.Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles.Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology.Quantitative cardiovascular magnetic resonance for molecular imaging.Variable antibody-dependent activation of complement by functionalized phospholipid nanoparticle surfaces.Molecular imaging of plaque vulnerability.Synergistic effect of antiangiogenic nanotherapy combined with methotrexate in the treatment of experimental inflammatory arthritis.alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers.Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases.Nanomedical Theranostics in Cardiovascular Disease.Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development MR molecular imaging of aortic angiogenesis.Angiogenesis is required for stress fracture healing in rats.Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbits Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles

P2860

Q26747500-DB155E23-AF21-4A9C-A5B2-21741F469C48 Q26795703-C3217640-B718-4A46-9D56-E831D0936071 Q27002916-C6CA8E7F-52BA-46CC-A8FC-A7B03534F265 Q27027613-6A085F1C-F93F-41CC-B94C-2F2CA7CCC332 Q30357131-1A8FD387-2638-404A-9BFA-D93E41FC102F Q30385272-0876F122-6A89-4C0E-A0A1-6DC2EB431032 Q30422169-43774930-889C-4B9D-B034-FE86640F3D33 Q30426880-68A0B8D5-65CC-41B8-9FB6-F0306A3A7168 Q30434516-C9D8FA31-1E01-49C1-AC3C-6DF3DB9AD33E Q30434964-4DAF287D-1EAB-4693-AA59-58F1E95FCCB7 Q30435383-F596DF7D-3058-40AD-8AFF-951C484A0943 Q30450131-642F4097-BDA7-4734-B166-34E29034D980 Q30452739-3AFFDEFE-355F-4CC9-A2A9-87DA2C3CD638 Q30455490-F0F61192-4D2B-4135-A31C-398CBA29CCCC Q30465710-5E126EC3-884E-4E56-AFC0-2ABBF6B93BF7 Q30474015-056D6B6E-D9EA-467A-9BC3-D983AB6E0063 Q30474418-0A591BBB-94C7-41C8-8830-66BA029B48C5 Q30474759-C733A4EE-7F89-4585-B94C-0205D7FB1203 Q30475719-DF6C938F-88A9-453E-9DBB-E7B65204DE5E Q30476207-56C8BFCB-1FB7-4D78-B98A-F15EE0646690 Q30481471-4EC47124-63CA-4211-9499-87D1EDE0F7F6 Q30487537-F7D3FCE0-89B2-48AB-806A-65511D5A227A Q33554945-93FCEB35-64E7-40DA-BDBA-7777BB1B73E0 Q34030709-9CB55F7E-CEAB-4FF0-BAF3-6E1F5F4A0F21 Q34033191-60AB8713-E89D-4BA8-A698-C193140BE055 Q34197669-C5CD111C-4B14-43A6-8956-F94422BD836F Q34330885-F42BFA94-3369-4ADF-9787-C11970DDFA76 Q34452451-C1A34F4A-555C-44D1-9E0E-856F80AF8AE3 Q34498697-D56B6807-CB14-41B0-B996-7D92E728F171 Q34562028-A5D0CE02-8623-4CC4-9FD8-EA593FE2001E Q34785222-71F563CB-4C50-4039-BBB9-338C8DA41654 Q35558487-6A342ED4-72F9-4948-AA16-BD4475A3FEC6 Q35667247-2EFC044D-F5CA-44F3-82E6-0937E7B8B1C3 Q35681183-B456F0A9-A7FF-4EAE-98F5-D31B701BCB74 Q35710262-1C0469FF-16A9-4672-9762-A452DAF73D7F Q36141999-F076DF83-E233-4A8A-9BC4-168918B1CFE2 Q36182417-72CF3693-68B9-4497-95F5-27B295ED005B Q36442977-8B8B6B16-7BEB-43BF-9F67-2537EAE3375A Q36483514-A6008400-CEF9-430F-B717-8D3D2E200B5E Q37039546-B54489A0-7B8D-4583-BECC-6FFA6A225DCE

P2860

Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis

http://www.wikidata.org/entity/Q37085672

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2008

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Antiangiogenic synergism of in ...... torvastatin in atherosclerosis

@en

Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.

@nl

type

label

Antiangiogenic synergism of in ...... torvastatin in atherosclerosis

@en

Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.

@nl

prefLabel

Antiangiogenic synergism of in ...... torvastatin in atherosclerosis

@en

Antiangiogenic synergism of in ...... orvastatin in atherosclerosis.

@nl

P1433

Q37085672-87B395F4-D218-4252-8686-4EBDF2F72135

P1476

Q37085672-1F0467FD-CC91-4074-AD49-9DD4248931CD

P2093

Q37085672-85297467-45A2-4100-8658-9AFB5F5D6F1C

Q37085672-8CC1B60E-6E66-4F67-BBDE-8E60BF4FDFFE

Q37085672-D2B20DB8-BBC1-4B9B-9890-F5F59BB557B7

Q37085672-DAAFB6A8-53C7-4C32-8F05-283AC7CEE522

Q37085672-F1CFC4D1-7AB5-4063-89DC-4F3CE7C1A92B

P2860

Q37085672-016AFE4F-08AA-4EAF-AF37-EDE96C1E2A6C

Q37085672-19620F72-58FE-4BD5-A148-679609EFB0BD

Q37085672-2B77E001-4E7E-4C74-B1E7-28FD98C46379

Q37085672-308BADBA-C171-477F-B53E-16AD6C7B0DA6

Q37085672-3AB73DEB-C53F-4417-837C-1661654016D9

Q37085672-424719BD-55A9-4E61-AB96-F3B1114CDCE3

Q37085672-42592F54-977D-4243-AC09-A149DCE8C480

Q37085672-433DF72C-B6E3-4531-BE28-23FA3616C9D1

Q37085672-486B801F-91C8-4D3D-B1DE-91E580518A72

Q37085672-4901444E-AD05-464A-948F-121DB0A6ADC7

P304

Q37085672-F89A9EBA-367C-4805-9DC7-376499BB941F

P31

Q37085672-5F89C39A-4455-428C-B609-0891258384B3

P356

Q37085672-0C189F5E-E466-4C50-B863-3780CDFA588C

P433

Q37085672-68B69E7B-D20B-40D3-8C27-0BCC21343B96

P478

Q37085672-2820C2BE-691E-483F-B370-101C03F08774

P50

Q37085672-4377135E-473A-41FF-A07E-446BE37A1074

P577

Q37085672-365C64E0-7095-448A-9DD3-54B47EFC2002

P5875

Q37085672-8CF86817-9D8D-4730-B248-68F91E20EE42

P698

Q37085672-13C9637A-3E4C-4048-8734-C3E9EA9074E0

P921

Q37085672-42B171B0-0408-4D6E-B23E-318DA97A351A

Q37085672-A47286EA-944D-4203-8D6C-C43ACBB9A37D

P932

Q37085672-3BEF6F11-C7B7-4564-A3A4-4BB2FF66D322

P356

J.JCMG.2008.06.003

P1433

JACC: Cardiovascular Imaging

P1476

Antiangiogenic synergism of in ...... torvastatin in atherosclerosis

@en

P2093

Gregory M Lanza

http://www.w3.org/2001/XMLSchema#string

Huiying Zhang

http://www.w3.org/2001/XMLSchema#string

Samuel A Wickline

http://www.w3.org/2001/XMLSchema#string

Shelton D Caruthers

http://www.w3.org/2001/XMLSchema#string

Todd A Williams

http://www.w3.org/2001/XMLSchema#string

P2860

Eukaryotic methionyl aminopeptidases: two classes of cobalt-dependent enzymes

Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2

Structure of human methionine aminopeptidase-2 complexed with fumagillin

Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.

Neovascularization in human atherosclerosis.

Granulocyte-macrophage and macrophage colony-stimulating factors differentially regulate alpha v integrin expression on cultured human macrophages

Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage.

Role of angiogenesis in cardiovascular disease: a critical appraisal.

Mechanisms of adverse effects of anti-VEGF therapy for cancer.

Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits

P304

624-634

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JCMG.2008.06.003

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P50

P577

2008-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24266675

http://www.w3.org/2001/XMLSchema#string

P698

19356492

http://www.w3.org/2001/XMLSchema#string

P921

atherosclerosis

P932

2636718

http://www.w3.org/2001/XMLSchema#string